Various studies suggested that baseline liver function has a significant impact on the efficacy of ICI therapy in advanced cancers [32–36]. For HCC, chronic liver disease could alter the immune microenvironment which has a significant influence on the anti-PD-1 therapy efficacy [37]. This evidence concerns the gene PDCD1 and cancer.